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Abstract
AIM: It is controversial whether patients with non-ulcer
dyspepsia (NUD) respond differently to Helicobacter pylori
(H pylori) eradication treatment than those with peptic ulcer
disease (PUD). To review the evidence for any difference
in H pylori eradication rates between PUD and NUD patients.
METHODS: A literature search for full articles and meeting
abstracts to July 2004 was conducted. We included
studies evaluating the efficacy of a proton pump inhibitor
(P) or ranitidine bismuth citrate (RBC) plus two antibiotics
of clarithromycin (C), amoxicillin (A), metronidazole (M),
or P-based quadruple therapies for eradicating the
infection.
RESULTS: Twenty-two studies met the criteria. No
significant difference in eradication rates was found
between PUD and NUD patients when treated with 7-d
RBCCA, 10-d PCA or P-based quadruple therapies. When
the 7-d PCA was used, the pooled H pylori eradication
rate was 82.1% (431/525) and 72.6% (448/617) for PUD
and NUD patients, respectively, yielding a RR of 1.15
(95%CI 1.01-1.29). However, the statistically significant
difference was seen only in meeting abstracts, but not in
full publications.
CONCLUSION: There is no convincing evidence to
suggest that NUD patients respond to H pylori eradication
treatments differently from those with PUD, although a
trend exists with the 7-d PCA therapy.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
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INTRODUCTION
It has been over 17 years since the first randomized,
placebo-controlled clinical trial of Helicobacter pylori (H pylori)
eradication was published[1]. Treatment to cure the infection
has evolved from single agents to combination treatment
regimens with up to four drugs. Currently, the most commonly
recommended combination treatments consist of a proton
pump inhibitor (P), clarithromycin (C) and amoxicillin (A)
or metronidazole (M)[2-4]. However, the success of treatment
with these combination regimens varies considerably between
reports[5]. Several factors have been identified to contribute
to the variability of the treatment outcomes. These include
patient- and treatment-related factors[5]. However, conflicting
results have been reported with regard to whether H pylori
eradication treatment is more effective in patients with peptic
ulcer disease (PUD) than in those with non-ulcer dyspepsia
(NUD) or other non-ulcer gastric diseases[6-11], especially
when patients are treated with the PCA combination regimen.
We undertook this meta-analysis to review systematically
the literature on H pylori eradication in patients with PUD
or with NUD and to evaluate the magnitude of any
difference in H pylori eradication rates between the two
groups of patients when treated with the most commonly
recommended treatment regimens.
MATERIALS AND METHODS
Search strategy
A computerized literature search for relevant studies was
performed in Cochrane Controlled Trials Register,
MEDLINE, PubMed, and EMBASE databases to June
2004 in all languages using the following MeSH terms or
textwords in various combinations: dyspepsia, NUD,
functional dyspepsia, peptic ulcer, PUD, H pylori, duodenal
ulcer, gastric ulcer, eradication. Several other online trials’
registries were also searched including United Kingdom
National Research Register (http://www.doh.gov.uk/
research/nrr.htm), Current Science register of controlled trials
(http://www.controlled-trials.com), ClinicalTrials.gov
developed by the National Library of Medicine (http://
www.clinicaltrials.gov/ct). A recursive hand search of
reference lists, review articles, editorials and abstracts from
major relevant international meetings was also conducted to
supplement electronic searches: American Digestive Disease
Week 1997-2004, the United European Gastroenterological
Week 1997-2003, American College of  Gastroenterology
Annual Meetings 1997-2003, the European H pylori Study
Group Meetings 1997-2003 and the World Congress of
Gastroenterology 1998-2002.
Inclusion and exclusion criteria
Because the research question of this study sought any
difference in H pylori eradication rates between patients with
PUD or NUD, the relative efficacy of different treatment
regimens was neither compared nor analyzed. Therefore,
we included all clinical trial designs if studies met the
following criteria: (1) any clinical trial in adults involving
one of the following combination regimens given in the
recommended doses: a PPI or ranitidine bismuth citrate
(RBC) plus two antibiotics (clarithromycin, amoxicillin,
metronidazole or tinidazole), and proton pump inhibitor-
based quadruple therapies; (2) studies which provided
comparative data on H pylori eradication rates between
patients with PUD and those with NUD; (3) studies which
provided raw data for intention-to-treat (ITT) analysis or
ITT data could be derived from the paper; (4) H pylori
infection was diagnosed by at least one of the following
methods: rapid urease test, histology, culture or urea breath
test; eradication was confirmed at least 4 wk after stopping
all medications. We excluded studies that reported mixed
eradication data or were identified as duplicate publications.
Studies of patients with chronic gastritis alone were also
excluded.
The eligibility criteria were assessed by two independent
reviewers (JQH and GFZ). Any disagreement about the
decision was solved through discussion to reach consensus
between the reviewers.
Data extraction
Two independent reviewers (JQH and GFZ) extracted the
data from the qualified studies and any disagreement was
resolved by discussions to reach consensus between the
reviewers. The following major items were extracted from
each qualified study: name of the first author, source and
date of publication, study design, demographics of patients,
diagnosis of H pylori infection and methods used for
confirmation of  eradication, details of  treatment regimen
(number of drugs, dose, dose frequency and treatment
duration), number of patients randomized, treated and
dropped-out, and number of patients with H pylori infection
eradicated by ITT analysis and by disease category (e.g.,
PUD, or duodenal ulcer or gastric ulcer or NUD).
Outcome measures
The only outcome concerned in this study was the H pylori
eradication rate by ITT analysis in patients with PUD
compared to those with NUD. Although we also extracted
eradication rates by per-protocol analysis, the data were not
presented due to concerns over the methodological
problems, such as information on drop-outs which was
poorly reported.
Assessment of study quality
The quality assessment was done independently by JQH
and GFZ. Because of the nature of our research question,
no existing scoring instruments could be used for conducting
the quality assessment. Therefore, we focused primarily on
the quality of presentation of study results such as whether
ITT H pylori eradication rates were clearly presented, etc.
Subgroup analysis
Studies were grouped by combination regimens including
different doses, treatment durations and types of publication
(meeting abstract, full article).
Statistical analysis
The minimum number of studies required for statistical
pooling was arbitrarily set at three and above. If only two
studies were available for any subgroup analysis, results
from the two studies were described and no pooling was
undertaken. The following statistical techniques were used
to analyze the data, wherever appropriate. Summary
relative risk, risk difference and 95% CI were calculated
from the raw data of the studies using a random-effects
model. The number-needed-to-treat (NNT) was also
calculated. The Cochrane Q method was used to test for
homogeneity. P<0.1 was considered to be statistically
significant for test of homogeneity. In the presence of
statistical heterogeneity, we searched for sources of
methodological heterogeneity. We also examined publication
bias by the method of  Egger’s regression[12]. All analyses
were performed with EasyMa software 2001 (M. Cucherat,
Lyon, France).
RESULTS
The literature search generated 502 citations. Browsing the
titles and abstracts reduced the number of citations to 246.
Of these potentially useful citations, 224 were subsequently
excluded for various reasons including review articles (n = 8),
no raw data (n = 104), unclear patient population (n = 68),
unlisted treatment regimens (n = 17), re-treatment (n = 15)
and duplicate publications (n = 13). A detailed list of the
excluded studies is available upon request.
Twenty-one studies met the predefined inclusion and
exclusion criteria and were subject to analysis[6-11,13-27].
RBC-containing regimens
RBC-containing triple or quadruple regimens were studied
in 6 trials involving 10 treatment comparisons[6,9,13-16].
Five studies were published in full[6,13-16] and one in abstract
form[9]. The treatment-related information from these
studies is tabulated in Table 1.
A total of 7 different combination regimens and 10
treatment arms were reported. Among the 10 treatment
arms, 7 were given for 7 d and three for 5 d. Because of
the large variability in drug combinations, meta-analysis was
not possible for most combination treatments (Table 1).
Triple therapies consisting of  RBC (R), clarithromycin (C)
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and tinidazole (T) were reported in two studies from the
same lead author. However, personal communication with
the corresponding author has excluded any duplication of
patients. No statistically significant difference in H pylori
eradication rate was observed in patients with PUD or NUD
treated with the 5-d RBT combination regimen in both
reports[9,13].
Three reports, involving RBC 400 mg, clarithromycin
500 mg and amoxicillin 1 g, all given twice daily for 7 d,
were considered appropriate for meta-analysis[6,15,16]. H pylori
eradication was achieved in 81.3% (52/64) of patients with
PUD and 85.2% (132/155) in those with NUD, yielding a
summary relative risk of 0.96 (95%CI 0.84-1.11); indicating
that triple therapy consisting of RBC, clarithromycin and
amoxicillin was similarly effective for eradicating H pylori
infection in patients with PUD compared to those with
NUD. The test of homogeneity was not statistically
significant (Q value = 1.1429, P = 0.56).
PPI-based quadruple combination treatments
We found five studies consisting of  six treatment arms that
provided comparative H pylori eradication data in PUD and
NUD patients[8,13,17-19]. Of these, four were published in
full[13,17-19] and one in abstract form[8]. Table 2 tabulates the
treatment-related characteristics of these studies. Because
of the large variability in the drug combinations, dose and
treatment duration among these studies, meta-analysis was
not possible. However, within study comparison did not
reveal any statistically significant difference in H pylori
eradication rates between patients with PUD and those with
NUD in any of  the combination regimens (Table 2).
PPI-based triple therapies
Nine studies and 10 treatment arms reported comparative
data involving triple therapies consisting of a PPI,
clarithromycin and amoxicillin[7-11,20-22,27]. Of these, seven
studies were only in abstract form[7-10,20-22] and two were
published in full[11,27].
Table 3 summarizes treatment-related information from
these studies.
Seven-day treatment involving a standard dose of PPI,
clarithromycin 500 mg and amoxicillin 1 g, all given twice
daily for 7 d, was used in six studies including 525 PUD
patients and 617 NUD patients[7,9,11,20,22,27]. H pylori eradication
was achieved in 82.1% of the 525 patients with PUD and
72.6% of the 617 patients with NUD, yielding a RR of
Table 1  Characteristics of RBC-containing triple and quadruple therapies
            Eradication rate (ITT)
Refs Combination regimens           Dose        Treatment duration  P
         PUD               NUD
   N/T.N (%)          N/T.N (%)
Triple therapies
RBCCA
  6 RBC/Cla/Amo 400 mg b.i.d./500 mg b.i.d./1 g b.i.d.        7 d 20/23 (86.96)           18/22 (81.8)
15 RBC/Cla/Amo 400 mg b.i.d./500 mg b.i.d./1 g b.i.d.        7 d 13/18 (72.2)           48/57 (84.2)
16 RBC/Cla/Amo 400 mg b.i.d./500 mg b.i.d./1 g b.i.d.        7 d 19/23 (82.6)           66/76 (86.8)
Others 52/64 (81.3)      132/155 (85.2)1
13 RBC/Cla/Tin 400 mg b.i.d./500 mg b.i.d./500 mg b.i.d.        5 d 20/27 (74.1)           23/39 (58.97)                  0.32
  9 RBC/Cla/Tin 400 mg b.i.d./500 mg b.i.d./500 mg b.i.d.        5 d      6/9 (66.7)              9/12 (75)                  0.95
16 RBC/Cla/Met 400 mg b.i.d./500 mg b.i.d./400 mg b.i.d.        7 d 20/21 (95.2)           69/78  (88.5)                  0.61
16 RBC/Met/Tet 400 mg b.i.d./400 mg b.i.d./1 g b.i.d.        7 d 38/46 (82.6)           43/54 (79.6)                  0.90
14 RBC/Fur/Tet 350 mg b.i.d./100 mg b.i.d./500 mg b.i.d.        7 d 20/24 (83.3)           31/36 (86.1)                  0.94
14 RBC/Fur/Amo 350 mg b.i.d./100 mg b.i.d./1 g b.i.d.        7 d 15/19 (78.95)           34/41 (82.9)                  0.99
Quadruple therapy
  6 RBC/Cla/Amo/Met 400 mg b.i.d./400 mg b.i.d./1 g b.i.d./500 mg b.i.d.      5 d               174/174 (100)          62/71  (87.3)               <0.05
RBC, ranitidine bismuth citrate; Cla, clarithromycin; Tin, tinidazole; Fur, furazolidone; Tet, tetracycline; Amo, amoxicillin; Met, metronidazole; b.i.d., twice daily; PUD,
peptic ulcer disease; NUD, non-ulcer dyspepsia; N/T.N, number/total number. 1Relative risk: 0.96 (95%CI 0.84–1.11).
Table 2  Characteristics of bismuth- or PPI-based quadruple therapies
           Eradication rate (ITT)
Refs Combination regimens   Dose          Treatment duration    P
      PUD                 NUD
N/T.N  (%)           N/T.N  (%)
17 CBS/Met/Tet/Lan 120 mg ×8/250 mg ×8/250 mg ×8/30 mg b.i.d.        1d 22/33 (66.7)               5/13 (38.5) 0.16
17 CBS/Met/Tet/Lan 120 mg ×8/250 mg ×8/250 mg ×8/30 mg b.i.d.        2 d 26/35 (74.3)            20/40 (50) 0.06
13 Amo/Cla/Tin/Ome 1 g b.i.d./500 mg b.i.d./500 mg b.i.d./20 mg b.i.d.        5 d1,2 30/31 (96.8)            31/34 (91.2) 0.68
18 Bis/Met/Tet/Lan 120 mg q.i.d./400 mg t.i.d./500 mg q.i.d./30 mg q.d.        7 d                 91/101 (90.1)       107/118 (90.7) 0.93
19 Bis/Met/Tet/Ome 120 mg q.i.d./400 mg t.i.d./500 mg q.i.d./30 mg q.d.      10 d 53/57 (93)            46/49 (93.9) 0.84
  8 Bis/Met/Tet/Ome 120 mg q.i.d./500 mg t.i.d./500 mg q.i.d./20 mg b.i.d.      14 d   9/11 (81.8)               8/13 (61.5) 0.53
CBS, colloidal bismuth subcitrate; Met, metronidazole; Tet, tetracycline; Lan, lansoprazole; Bis, bismuth; Cla, clarithromycin; Rab, rabeprazole; Tin, tinidazole; Amo,
amoxicillin; ×8, 8 times daily; q.i.d., four times daily; q.d., once daily; b.i.d., twice daily; Ome, omeprazole. 1Rabeprazole and amoxicillin were used on d 1-5, clarithromycin
and tinidazole on d 6-10; 2amoxicillin was used on d 1-5, clarithromycin and tinidazole on d 6-10, and omeprazole on d 1-10. PUD, peptic ulcer disease; NUD, non-ulcer
dyspepsia; N/T.N, number/total number.
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1.15 (95%CI 1.01-1.29). However, the test of homogeneity
showed the presence of statistically significant between-study
heterogeneity (Q Cochrane = 11.81, df = 5, P = 0.037).
Scrutiny of these studies found that the heterogeneity
was most likely caused by a large differential difference in
H pylori eradication rates between studies. Therefore, a
random-effects model was used, which yielded a RR of
1.15 (95%CI 1.01-1.29). The result suggests that the 7-d
PCA combination regimen given in the recommended doses
cured significantly more H pylori infections in patients with
PUD than in those with NUD. The summary risk difference
was estimated at 0.11 (95%CI -0.01-0.22), giving an estimated
NNT of  9. The Egger’s regression test for the detection
of publication bias was not statistically significant (r = -0.64,
P = 0.08) for the 7-d PCA triple therapy.
Figure 1 depicts the individual and summary relative
risks and 95%CI.
Figure 1  Individual and summary relative risks and 95% CI comparing the
efficacy of 7 d PCA combination regimen in patients with PUD or NUD.
A subgroup analysis was conducted according to the
type of publication. Of the six studies, four were published
in abstract form[7,9,20,22] and two as full articles[11,27]. The
pooled eradication rates from the four meeting abstracts
were 85.8% for patients with PUD and 69.7% for those
with NUD, yielding a RR of 1.19 (95%CI 1.06-1.33).
However, the test of homogeneity was statistically significant
(Q Cochrane: 8.47, P = 0.037). A reanalysis of the data
using a random-effects model generated a RR of 1.23
(95%CI 1.00-1.52), demonstrating a borderline statistically
significant difference, indicating a trend that patients with
PUD respond to the 7-d PCA combination treatment better
than those with NUD.
Similar eradication rates were observed in the two
reports published as full articles[11,27]. An Italian study
reported by Zullo and colleagues showed similar H pylori
eradication rates between patients with PUD (74.8%) and
those with NUD (73.5%)[11] (Table 3). A US study reported
by Vakil et al[27], demonstrated that PCA eradicated 8.2%
more H pylori infections in patients with PUD than in those
with NUD (Table 3). However, this difference was not
statistically significant.
Sato and colleagues reported one study, involving two
treatment arms, in which higher doses of  antibiotics were
used in 7-d PCA combination[10]. However, no significant
difference in H pylori eradication rates between the two
groups of  patients was reported (Table 3).
Three studies reported efficacy data obtained with a
10-d standard dose PCA combination regimen involving
309 PUD patients and 300 NUD patients[8,21,27]. The pooled
eradication rate was 74.8% (231/309) for PUD patients
and 77% (231/300) for NUD patients, respectively, yielding
a RR of 1.03 (95%CI 0.95-1.12). The test of homogeneity
was not statistically significant (Q Cochrane: 2.81, P = 0.42).
Thus, there was no statistically significant difference in
H pylori eradication rate between the two groups of patients.
Four studies (five arms) reported comparative eradication
data involving triple therapies consisting of a PPI,
metronidazole and clarithromycin or amoxicillin[23-26]. The
results of  these studies are tabulated in Table 4. However,
no statistically significant difference in H pylori eradication
Table 3  Characteristics of triple therapies consisting of a PPI, clarithromycin and amoxicillin
 Eradication rate (ITT)
Refs            Combination regimens Dose                  Treatment
               duration (d)            PUD          NUD P
     N/T.N (%)    N/T.N (%)
22            Ome/Cla/Amo            20 mg b.i.d./500 mg b.i.d./1 g b.i.d.        7 134/161 (83.2)      34/42 (81)
  7            Ome/Cla/Amo            20 mg b.i.d.1/500 mg b.i.d./1 g b.i.d.        7      60/65 (92.3)      30/50 (60)
  9            PPI/Cla/Amo            PPI b.i.d./500 mg b.i.d./1 g b.i.d.        7      27/34 (79.4)      15/21 (71.4)
11            Rab/Cla/Amo            20 mg b.i.d./500 mg b.i.d./1 g b.i.d.        7 101/135 (74.8) 288/392 (73.5)
20            Pan/Cla/Amo            40 mg b.i.d./500 mg b.i.d./1 g b.i.d.        7      27/29 (93.1)      13/19 (68.4)
27            Rab/Cla/Amo            20 mg b.i.d./500 mg b.i.d./1 g b.i.d.        7   82/101 (81.2)      68/93 (73)
431/525 (82.1)  448/617 (72.6)2
10            Ome/Cla/Amo            40 mg b.i.d./800 mg b.i.d./2 g b.i.d.        7      87/98 (88.8)          6/6  (100)               0.388
10            Ome/Cla/Amo            40 mg b.i.d./1.6 g b.i.d./2 g b.i.d.        7      51/51 (100)      49/50 (98)               0.313
  8            Lan/Cla/Amo            30 mg b.i.d./500 mg b.i.d./1 g b.i.d.      10      13/13 (100)      65/71 (91.6)
21            Ome/Cla/Amo            20 mg b.i.d./500 mg b.i.d./1 g b.i.d.      10      63/96 (65.6)      20/27 (74.1)
27            Rab/Cla/Amo            20 mg b.i.d./500 mg b.i.d./1 g b.i.d.      10      75/97 (77.3)      78/99 (78.8)
27            Ome/Cla/Amo            20 mg b.i.d./500 mg b.i.d./1 g b.i.d.      10   77/103 (74.8)    68/103 (73.1)
231/309 (74.8) 231/300 (77)3
Ome, omeprazole; Lan, lansoprazole;  Pan, pantoprazole; Rab, rabeprazole; Cla, clarithromycin; Amo, amoxicillin; daily; q.d., daily; b.i.d., twice daily. 1Omeprazole was used
for 2 wk. PUD, peptic ulcer disease; NUD, non-ulcer dyspepsia; PPI b.i.d., PPI in standard dose. 2RR (95%CI): 1.15 (1.01–1.29). 3RR (95%CI): 1.03 (0.95–1.12). N/T.N, number/
total number.
0    0.2   0.4   0.6  0.8   1.0   1.2   1.4   1.6  1.8   2.0
            Favors NUD  RR and 95%Cl Favors PUD
Reference (1sh author, year)
Borda et al, 1999
Catalano et al, 1997
De Francesco et al, 2001
Zullo et al, 2003
Luna et al, 1997
Vakil et al, 2004
Summary RR (95%Cl)
(random-effects model) 1.15 (1.03-1.29)
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rates between patients with PUD and those with NUD was
reported in any of the studies[23-26].
DISCUSSION
Individual studies suggest that patients with PUD may
respond better to H pylori eradication treatment than patients
with NUD. However, the results have been conflicting
between studies[6-11]. Several factors may have contributed
to the conflicting reports, which include a small sample
size[10,17,24,25], use of sub-optimal doses or inadequate
treatment duration[13,17]. In order to systematically examine
this question, we comprehensively reviewed all relevant
clinical trials that provided data on H pylori eradication
between patients with PUD and those with NUD.
Although there are numerous combination treatment
regimens for eradicating H pylori infection, only a few choices
of treatments are currently recommended[2-4,28,29]. Therefore,
we focused on the combination treatment regimens that
are currently recommended by the majority of authorities
or consensus groups. These include triple therapies consisting
of a PPI or RBC plus two antibiotics (clarithromycin,
amoxicillin or metronidazole) or PPI-based quadruple
therapies[2-4,28,29].
No significant difference in the H pylori eradication rate
was observed between patients with PUD and those with
NUD when RBC-based triple therapies were used,
irrespective of the combination of antibiotics, dose regimens
and treatment duration (Table 1). Similar results were also
found in patients treated with PPI-based quadruple therapies
(Table 2), suggesting that both RBC-based triple therapies
and PPI-based quadruple combination therapies are similarly
effective for eradicating H pylori infection in patients with
PUD or with NUD.
PPI-based triple therapies are the most commonly
recommended treatment choice for eradicating H pylori
infection because of their highly consistent efficacy and
excellent safety record[30,31]. However, the number of studies
that included both PUD and NUD patients was limited and
this has prohibited us from conducting a reliable meta-
analysis of all the recommended PPI-based triple therapies.
We found that, with the exception of  the 7-d PCA combination,
no significant differences in H pylori eradication rates have
been observed in patients with PUD or NUD when other
PPI-based triple therapies were used (Table 4). Among the
six studies using the recommended PCA treatment, 9.5%
more H pylori infections were cured in patients with PUD
compared to those with NUD, which is statistically
significant. However, the results from the subgroup
analysis by publication type showed that the difference
was caused by a large differential difference (16.1%)
observed in the meeting abstracts because there was no
statistically significant difference in the H pylori eradication
rates between the two groups of patients in the two full
articles[11,27]. Therefore, according to the current literature,
there is no convincing evidence that patients with NUD
respond to the 7-d PCA combination treatment significantly
different from those with PUD. This is especially the case
when the PCA combination treatment is used for 10 d
and similar H pylori eradication rates are achieved in both
groups of patients[8,21,27].
Nevertheless, Houben and colleagues observed that PPI-
based triple therapies eradicated 8.8% more H pylori
infections in patients with PUD than in those with NUD
(P = 0.036)[32]. However, this study was published in abstract
form and no detailed information on treatment regimens
was provided[32]. A similar, but statistically non-significant
difference was also reported by Kamberoglou et al[33], in a
study involving 106 NUD and 142 PUD patients treated
with either PPI- or RBC-based triple therapies in which
8.1% more H pylori infections were cured in patients with
PUD than in those with NUD. Similarly, the study was only
available in abstract form. Furthermore, the authors did
not separate patients treated with PPI-based therapies from
those receiving RBC-based regimens, making it difficult to
ascertain which combination treatment contributed most
to the observed difference.
Why patients with NUD and PUD respond differently
to the 7-d PCA combination regimen remains unclear.
Several hypotheses suggested by Gisbert and colleagues
indicate that infection with different strains of H pylori,
different severities of inflammation or patient compliance,
age and gender may contribute to differences in H pylori
eradication rates between patients with PUD and NUD[6].
Nevertheless, it is not clear why the difference was only
seen with the 7-d PCA combination treatment, but not with
other treatment regimens.
We combined patients with duodenal ulcer or gastric
ulcer in this study because the evidence from individual
studies suggests no significant difference in H pylori
eradication rates between patients with duodenal or gastric
ulcer when the PCA combination[10,21,22] or other PPI-based
Table 4  Characteristics of triple therapies consisting of a PPI, metronidazole and clarithromycin or amoxicillin
               Eradication rate (ITT)
Refs              Combination regimens      Dose    Treatment duration     P
        PUD    NUD
  N/T.N (%)                 N/T.N (%)
23              Pan/Met/Cla              40 mg q.d./400 mg b.i.d./250 mg b.i.d.                    7 d 54/65 (83.1)               21/24 (87.5) 0.613
23              Pan/Met/Cla              40 mg b.i.d./400 mg b.i.d./250 mg b.i.d.                    7 d 54/64 (84.4)               18/22 (81.8) 0.781
24              Ome/Met/Cla              40 mg q.d./500 mg b.i.d./250 mg b.i.d.                    7 d 15/19 (78.95)                    5/6 (83.3) 0.819
25              Pan/Met/Amo              40 mg b.i.d./500 mg b.i.d./1 g b.i.d.                    7 d 14/19 (73.7)                  7/11 (63.6) 0.569
26              Ome/Met/Amo              40 mg q.d./400 mg t.i.d.1/750 mg b.i.d.                 14 d 22/27 (81.5)               22/37 (59.5) 0.063
Ome, omeprazole; Pan, pantoprazole; Cla, clarithromycin; Amo, amoxicillin; Met, metronidazole; daily; q.d., daily; b.i.d., twice daily. 1Metronidazole was used
for 5 d only. PUD, peptic ulcer disease; NUD, non-ulcer dyspepsia.
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triple therapy[19] was used. The results show that H pylori
infection-related gastric or duodenal ulcers respond similarly
to eradication treatment.
There are several limitations to our study. First, the
nature of the study question which we assessed indicates
that there are no randomized controlled clinical trials.
Therefore, we included all study designs in the analysis
and these may suffer from certain methodological
weaknesses. Second, the number of trials available for
analysis was limited especially for non-PCA combination
regimens. Therefore, a type II error cannot be excluded.
The small number of studies also prohibited us from
conducting several clinically important subgroup analyses
to assess the potential impact of bacterial resistance,
different strains of H pylori and the country of study on
the difference in H pylori eradication rates.
In conclusion, although individual studies may have
suggested that patients with PUD respond better to H pylori
eradication treatment than those with NUD, we have not
found any convincing evidence that this is the case across
different combination treatment regimens although a trend
exists with the recommended 7-d triple therapy consisting
of a standard dose proton pump inhibitor, clarithromycin
and amoxicillin.
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